These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 29925695)

  • 1. A porcine model of neurofibromatosis type 1 that mimics the human disease.
    White KA; Swier VJ; Cain JT; Kohlmeyer JL; Meyerholz DK; Tanas MR; Uthoff J; Hammond E; Li H; Rohret FA; Goeken A; Chan CH; Leidinger MR; Umesalma S; Wallace MR; Dodd RD; Panzer K; Tang AH; Darbro BW; Moutal A; Cai S; Li W; Bellampalli SS; Khanna R; Rogers CS; Sieren JC; Quelle DE; Weimer JM
    JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease.
    Abramowicz A; Gos M
    Dev Period Med; 2014; 18(3):297-306. PubMed ID: 25182393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Legius syndrome, an Update. Molecular pathology of mutations in SPRED1.
    Brems H; Legius E
    Keio J Med; 2013; 62(4):107-12. PubMed ID: 24334617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel mutation in NF1 gene of patient with Neurofibromatosis type 1: A case report and functional study.
    Zhang T; Jia C; Dong Z; Li C; Lu W
    Mol Genet Genomic Med; 2021 May; 9(5):e1643. PubMed ID: 33764694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel NF1 mutation in a Chinese patient with giant café-au-lait macule in neurofibromatosis type 1 associated with a malignant peripheral nerve sheath tumor and bone abnormality.
    Tong HX; Li M; Zhang Y; Zhu J; Lu WQ
    Genet Mol Res; 2012 Aug; 11(3):2972-8. PubMed ID: 22869071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.
    Hirata Y; Brems H; Suzuki M; Kanamori M; Okada M; Morita R; Llano-Rivas I; Ose T; Messiaen L; Legius E; Yoshimura A
    J Biol Chem; 2016 Feb; 291(7):3124-34. PubMed ID: 26635368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofibromatosis type 1 (NF1) gene: Beyond café au lait spots and dermal neurofibromas.
    Peltonen S; Kallionpää RA; Peltonen J
    Exp Dermatol; 2017 Jul; 26(7):645-648. PubMed ID: 27622733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant Peripheral Nerve Sheath Tumor in an Army Reservist With Neurofibromatosis Type 1.
    Kou CJ; Rendo M; Broadwater DR; Beeler B
    Mil Med; 2021 May; 186(5-6):e626-e631. PubMed ID: 33180928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel phenotypes of NF1 patients from unrelated Chinese families with tibial pseudarthrosis and anemia.
    Banerjee S; Lei D; Liang S; Yang L; Liu S; Wei Z; Tang JP
    Oncotarget; 2017 Jun; 8(24):39695-39702. PubMed ID: 27980226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic analyses of mosaic neurofibromatosis type 1 with giant café-au-lait macule, plexiform neurofibroma and multiple melanocytic nevi.
    Hida T; Idogawa M; Okura M; Sugita S; Sugawara T; Sasaki Y; Tokino T; Yamashita T; Uhara H
    J Dermatol; 2020 Jun; 47(6):658-662. PubMed ID: 32246533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Independent NF1 and PTPN11 mutations in a family with neurofibromatosis-Noonan syndrome.
    Thiel C; Wilken M; Zenker M; Sticht H; Fahsold R; Gusek-Schneider GC; Rauch A
    Am J Med Genet A; 2009 Jun; 149A(6):1263-7. PubMed ID: 19449407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotype-phenotype associations in neurofibromatosis type 1 (NF1): an increased risk of tumor complications in patients with NF1 splice-site mutations?
    Alkindy A; Chuzhanova N; Kini U; Cooper DN; Upadhyaya M
    Hum Genomics; 2012 Aug; 6(1):12. PubMed ID: 23244495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel and Recurring Disease-Causing NF1 Variants in Two Chinese Families with Neurofibromatosis Type 1.
    Xiao H; Yuan L; Xu H; Yang Z; Huang F; Song Z; Yang Y; Zeng C; Deng H
    J Mol Neurosci; 2018 Aug; 65(4):557-563. PubMed ID: 30046999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1.
    Klose A; Ahmadian MR; Schuelke M; Scheffzek K; Hoffmeyer S; Gewies A; Schmitz F; Kaufmann D; Peters H; Wittinghofer A; Nürnberg P
    Hum Mol Genet; 1998 Aug; 7(8):1261-8. PubMed ID: 9668168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NF1
    Swier VJ; White KA; Negrão de Assis PL; Johnson TB; Leppert HG; Rechtzigel MJ; Meyerholz DK; Dodd RD; Quelle DE; Khanna R; Rogers CS; Weimer JM
    Clin Transl Sci; 2024 Jun; 17(6):e13858. PubMed ID: 38932491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a Novel
    Xu G; Li M; Niu Y; Huang X; Li Y; Tang G; Long S; Zhao H; Jiang H
    Biomed Res Int; 2019; 2019():2721357. PubMed ID: 31886188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofibromin-deficient Schwann cells have increased lysophosphatidic acid dependent survival and migration-implications for increased neurofibroma formation during pregnancy.
    Nebesio TD; Ming W; Chen S; Clegg T; Yuan J; Yang Y; Estwick SA; Li Y; Li X; Hingtgen CM; Yang FC
    Glia; 2007 Apr; 55(5):527-36. PubMed ID: 17236191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenic Mutations Associated with Legius Syndrome Modify the Spred1 Surface and Are Involved in Direct Binding to the Ras Inactivator Neurofibromin.
    Führer S; Tollinger M; Dunzendorfer-Matt T
    J Mol Biol; 2019 Sep; 431(19):3889-3899. PubMed ID: 31401120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and management of neurofibromatosis type 1.
    Korf BR
    Curr Neurol Neurosci Rep; 2001 Mar; 1(2):162-7. PubMed ID: 11898512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Jaffe-Campanacci syndrome, revisited: detailed clinical and molecular analyses determine whether patients have neurofibromatosis type 1, coincidental manifestations, or a distinct disorder.
    Stewart DR; Brems H; Gomes AG; Ruppert SL; Callens T; Williams J; Claes K; Bober MB; Hachen R; Kaban LB; Li H; Lin A; McDonald M; Melancon S; Ortenberg J; Radtke HB; Samson I; Saul RA; Shen J; Siqveland E; Toler TL; van Maarle M; Wallace M; Williams M; Legius E; Messiaen L
    Genet Med; 2014 Jun; 16(6):448-59. PubMed ID: 24232412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.